Bicara Therapeutics (BCAX) Operating Expenses (2023 - 2026)

Bicara Therapeutics has reported Operating Expenses for 4 years, with the latest figure at $60.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 44.16% year-over-year to $60.2 million; the trailing twelve-month figure through Mar 2026 stood at $174.1 million (up 59.98% YoY), and the FY2025 full-year result was $155.6 million, up 88.87% from the prior year.
• Operating Expenses for Q1 2026 stood at $60.2 million, up from $41.1 million in the prior quarter.
• The five-year high for Operating Expenses was $60.2 million in Q1 2026, with the low at $9.5 million in Q3 2023.
• Historically, Operating Expenses has averaged $29.2 million across 4 years, with a median of $26.6 million in 2024.
• Annual changes were most pronounced in 2025 — Operating Expenses jumped 171.81% — and 2026, when it jumped 44.16%.
• Bicara Therapeutics' Operating Expenses stood at $13.7 million in 2023, then jumped by 94.62% to $26.6 million in 2024, then soared by 54.38% to $41.1 million in 2025, then soared by 46.5% to $60.2 million in 2026.
• The last three Operating Expenses figures came in at $60.2 million (Q1 2026), $41.1 million (Q4 2025), and $40.7 million (Q3 2025), per Business Quant data.